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Independence of 
albuminuria and 
estimated glomerular 
filtration rate as 
outcome predictors for 
end-stage renal disease
As they report in this issue, Gansevoort 
et al. examined the interaction of 
albuminuria and estimated glomerular 
filtration rate (eGFR) in predicting the 
outcomes of patients with chronic kidney 
disease. In a meta-analysis of close to a 
million subjects in the general popula-
tion, the risk for end-stage renal disease 
(ESRD) was not related to an eGFR of 
75–105 ml/min per 1.73 m2 but increased 
exponentially at lower levels of eGFR. In 
all subjects tested, the risk increased as 
the eGFR declined. Albuminuria also was 
exponentially related to the risk of ESRD. 
Interestingly, there was no interaction of 
CCR2 blocker in 
diabetic nephropathy
Progression of renal failure in diabetic 
nephropathy is associated with infil-
tration of macrophages that express 
CCR2 receptors. Sayyed et al. used a 
small-molecule receptor blocker that 
is orally active (RO5234444). The con-
sequence of blockade is prevention of 
chemotaxis in in vitro assays. Here, the 
authors used this reagent in db/db mice 
(a type 2 diabetes model) that had one 
kidney removed. The dose was titrated 
so that it would block the receptor but 
not influence total leukocyte number. 
The authors found a reduction of the 
number of macrophages in the glomer-
ulus. Further, there was a reduction of 
apoptosis in the glomerulus, a signal 
event in the development of diabetic 
nephropathy. There were also less albu-
minuria and glomerulosclerosis in the 
treated mice than in controls. This study 
shows a promising preclinical test for 
this reagent. See page 68.
eGFR and albuminuria. Also, a history of 
acute kidney injury was a good predictor 
for ESRD. See page 93.
Biosimilar 
erythro poietin  
also produces 
neutralizing antibodies
It is fair to say that the use of recombinant 
human erythropoietin (r-HuEpo) for the 
treatment of anemia in chronic kidney 
disease has revolutionized renal therapy 
in end-stage renal disease. The large 
profit accrued to the firm that generated 
r-HuEpo has not gone unnoticed, and a 
number of new reagents have been pro-
duced by others that ostensibly remove 
some of the problems of the original for-
mulation, including the loss of activity 
due to generation of anti-r-HuEpo anti-
bodies. Praditpornsilpa et al. investigated 
these ‘biosimilar’ products, specifically to 
determine whether neutralizing antibod-
ies are generated as in the traditional for-
mulation. Thirty patients taking the new 
formulations developed sudden loss of 
efficacy, and their sera were studied. Most 
of these sera (23 of 30) had neutralizing 
antibodies. The bone marrow from these 
patients indicated pure red-cell aplasia, 
confirming the loss of erythropoietin 
activity. The other patients lost efficacy 
because of occult gastrointestinal bleed-
ing. We note that ‘biosimilar,’ unfortu-
nately, has different meanings in different 
countries, largely due to regulatory issues 
that are country specific. Hence, readers 
are warned to treat this word with cau-
tion when they encounter it in scientific 
publications. See page 88.
